Compile Data Set for Download or QSAR
Report error Found 682 Enz. Inhib. hit(s) with Target = 'Vascular endothelial growth factor A' Sort by
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107697(US8722895, 3: {[5-(4-Cyano-phenyl)-3-hydroxy-pyrid...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataEC50:  4.21E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107699(US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  7.70E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107702(US8722895, 8: {[5-(4-Cyanophenyl)-3-hydroxypyridin...)
Affinity DataEC50:  4.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataEC50:  7.60E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107707(US8722895, 13: {[5-(4-Isopropylphenyl)-3-hydroxypy...)
Affinity DataEC50:  1.50E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107708(US8722895, 14: {[5-(4-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxy...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hy...)
Affinity DataEC50:  3.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataEC50:  1.40E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107712(US8722895, 18: {[5-(3-Cyano-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107713(US8722895, 19: ({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107714(US8722895, 20: {[5-(3-Cyanophenyl)-3-hydroxypyridi...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy-...)
Affinity DataEC50:  5.01E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US8722895, 22: ({3-Hydroxy-5-[3-(pyrrolidine-1-car...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US8722895, 23: ({3-Hydroxy-5-[3-(pyrrolidine-1- ca...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107718(US8722895, 24: ({3-Hydroxy-5-[3-(2H-tetrazol-5-yl)...)
Affinity DataEC50: >1.00E+5nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2014
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50017345(CHEMBL3288260)
Affinity DataKd:  1.40E+4nMAssay Description:Binding affinity to human recombinant VEGF165 by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2015
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50017346(CHEMBL3288258)
Affinity DataKd:  6.60E+4nMAssay Description:Binding affinity to human recombinant VEGF165 by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2015
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50017347(CHEMBL3288259)
Affinity DataKd:  8.60E+4nMAssay Description:Binding affinity to human recombinant VEGF165 by surface plasmon resonance assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2015
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50179255(N-[(2S,3S,4S,5S,6R)-3-{[(2R,3S,4S,5R,6R)-4-{[(2R,3...)
Affinity DataKd:  7.10nMAssay Description:Binding affinity for VEGF by BIAcore solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50179254((2R,3S,4S,5S,6R)-2-{[(2R,3S,4S,5R,6R)-2-{[(2R,3S,4...)
Affinity DataKd:  1.70nMAssay Description:Binding affinity for VEGF by BIAcore solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50179256(6-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d...)
Affinity DataKd:  7.20nMAssay Description:Binding affinity for VEGF by BIAcore solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50179253((2R,3S,4S,5S,6R)-2-{[(2R,3S,4S,5R,6R)-2-{[(2R,3S,4...)
Affinity DataKd:  1.70nMAssay Description:Binding affinity for VEGF by BIAcore solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM372960(US9896418, Compound 1 | US10597366, Compound 1)
Affinity DataEC50:  250nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM372961(US9896418, Compound 2 | US10597366, Compound 2)
Affinity DataEC50:  62nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM372964(US9896418, Compound 8 | US10597366, Compound 8)
Affinity DataEC50:  33nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM372966(US9896418, Compound 9 | US10597366, Compound 9)
Affinity DataEC50:  6nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421295(CHEMBL2087907)
Affinity DataKd:  9.10E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421296(CHEMBL2087888)
Affinity DataKd:  7.60E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421298(CHEMBL2087889)
Affinity DataKd:  7.70E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421299(CHEMBL2087890)
Affinity DataKd:  1.09E+5nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421300(CHEMBL2087891)
Affinity DataKd:  1.70E+6nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421297(CHEMBL2087893)
Affinity DataKd:  1.20E+6nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421301(CHEMBL2087894)
Affinity DataKd:  1.00E+6nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421302(CHEMBL2087895)
Affinity DataKd:  4.53E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421303(CHEMBL2087896)
Affinity DataKd:  2.80E+5nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421316(CHEMBL2087898)
Affinity DataKd:  2.07E+5nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421305(CHEMBL2087899)
Affinity DataKd:  1.04E+5nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421306(CHEMBL2087900)
Affinity DataKd:  5.45E+5nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421307(CHEMBL2087901)
Affinity DataKd:  1.10E+6nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421308(CHEMBL2087903)
Affinity DataKd:  8.10E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421317(CHEMBL2087904)
Affinity DataKd:  4.02E+5nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421309(CHEMBL2087905)
Affinity DataKd:  7.66E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421310(CHEMBL2087906)
Affinity DataKd:  2.90E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM50421311(CHEMBL2087908)
Affinity DataKd:  4.00E+4nMAssay Description:Binding affinity to VEGF by surface plasmon resonance-based solution affinity assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2013
Entry Details Article
PubMed
Displayed 1 to 50 (of 682 total ) | Next | Last >>
Jump to: